Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243358 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
A Phase 2 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02243358 is a Phase 2 study that has completed, run by Henry Ford Health System. The registered enrollment target is 24 participants.
The verdict
NCT02243358, a Phase 2 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
Interventions
- RADIATION Radiation Therapy
- DRUG Gemcitabine
- DRUG Folfox6
- PROCEDURE Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-02 |
| Est. Completion | 2020-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02243358
The ClinicalTrials.gov registry entry for NCT02243358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT02243358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02243358 about?
NCT02243358 is a clinical study titled "Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer". To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
What is the current status of trial NCT02243358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2014-02. Estimated completion is 2020-01-14.
What interventions are being tested in trial NCT02243358?
The interventions under investigation include: Radiation Therapy (RADIATION), Gemcitabine (DRUG), Folfox6 (DRUG), Pancreaticoduodenectomy with retroperitoneal lymphadenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02243358?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.